MIVT.OB~~Sector: Healthcare~~Industry: Medical Equipment & Supplies

[setravis]

I'm glad tomorrow is Friday......TGIF.
I got to recoup after this week.......

[422fwhp]

I sold with a decent profit the day after my last post.  I'm looking to re-enter.  It bounced off the 50(MA) and is at the just above the lower bollinger band.  IMO, all we need is volume.

News today:
MIV Therapeutics' Intellectual Property Portfolio Expands to 43 Patents, Patent Applications and Licenses on Novel Technologies

Aggressive IP Protection of Coating Technologies Positions Company for Entry into $100 Billion Drug-Delivery Market


VANCOUVER, British Columbia--(BUSINESS WIRE)--Sept. 26, 2005--MIV Therapeutics, Inc. (OTCBB:MIVT - News; Frankfurt/FSE:MIV), a developer of next-generation biocompatible passive and drug-eluting stent coatings and drug delivery technologies for the treatment of cardiovascular disease, has announced that its intellectual property portfolio has achieved a total of 43 U.S. and international patents and patent applications. Aggressive steps taken to secure patent protection for the IP portfolio reflect the Company's vision and business strategy to generate significant revenues from its proprietary coating solutions, targeting the projected $100 billion dollar global marketplace for coronary stents and advanced drug-delivery systems.

The Company's intellectual property portfolio includes patents held by the University of British Columbia (UBC) to which MIVT has exclusive commercial rights under a strategic alliance with the university. The latest count includes several key patent applications filed simultaneously in various countries around the world, further protecting commercial exclusivity of MIVT's inventions in the global marketplace. The patents from UBC involve MIVT's initial strategic thrust to commercialize a family of next-generation biocompatible coatings for stents and other medical devices based on a highly biocompatible material called Hydroxyapatite (HAp), which has been shown to be suitable for a broad array of applications as a coating for coronary stents and next-generation drug-elution/drug-delivery systems.

"The vigorous expansion and the aggressive protection of intellectual property portfolio is a central element of MIVT's high-growth business strategy. Continued growth of our family of patents, licenses and patent applications reflects methodical pursuit of important milestones of our corporate progress," said Alan Lindsay, Chairman and CEO of MIVT. "Our HAp-based coatings and composite drug delivery technologies have a number of potential broad applications in cardiovascular and non-vascular drug/device combination products. Our goal is to continue to develop innovative solutions needed in our target markets and to diversify our portfolio of solutions to capitalize on applications that can access the $100 billion market of combination implantable drug delivery systems."

Mr. Lindsay added, "The market for drug-eluting stents is one of the fastest growing segments within the medical device arena, with annual growth approaching 25%, and there is a critical need for next-generation technologies and solutions to enhance the performance and safety of devices, while providing competitive advantages to medical device manufacturers."

In addition to its advanced research and development programs, the Company is also expanding its intellectual property portfolio through acquisitions. Earlier this year, MIVT grew its IP portfolio through acquisition of SagaX, a company developing a range of proprietary solutions to prevent naturally occurring cardio-embolic strokes and strokes and other common and serious complications that can result from cardiac procedures. These technologies include an innovative proprietary Aortic Embolic Protection Device (AEPD),designed to be implanted in the aorta during cardiology surgery and procedures, to filter and/or deflect embolic particles that can cause seriously debilitating or fatal strokes if left in blood circulation. The unique AEPD technology being developed at MIVT's SagaX subsidiary is one of the latest innovations in the field of filter-based embolic protection devices. It is the only filter being developed for use in the aorta. SagaX is also developing other proprietary embolic protection technologies.

The global market for carotid stents and embolic filters, which are frequently implanted in combination with each other for stroke prevention purposes, is growing around the world. Currently, the global market for these devices is estimated at $130 million, but analysts forecast that such devices will grow into a $500 million to $1 billion segment of the stent market, according to published reports.

[setravis]

Very good news out......
I think this ready to rock and roll again!

[setravis]

Very good news out......
I think this ready to rock and roll again!

And sure enough yesterday's good news put this one back in high gear today.
The rock and roll!!!!

[gmarc66]

Great call Setravis!!!


julia

[runforthedoor]

  News that could give this one another leg up....share tartget uped to $2.50....

  http://www.purepennies.com/otcbb_news.shtml

[422fwhp]

A great trade!

I took profits at $1.55

APPLAUD for a great pic.

[setravis]

News that could give this one another leg up....share tartget uped to $2.50....

http://www.purepennies.com/otcbb_news.shtml

" MIV Therapeutics' Six-Month Share Price Target Raised 100% to $2.50 in Newly Available Report from SISM Research"
Business Wire (Fri 3:30am) 

That's a great site you posted the link to...I have always liked.....
purepennies.com

This stock is making a nice run.
Bounced very nice of the 50-day MA and after the 50% fibonacci retracement.
Support @ 1.37...1.28...1.09
Resistance @ 1.55...1.83
MACD is bullish

Technicals
Last Price Quote is:
19.12%above 13-day EMA
37.31%above 50-day EMA

[setravis]

Looks to be building up steam on this train...for a breakout.

[422fwhp]

I believe you'll find another test of your drawn support line.  I got a great price today and I'm sure many others did, too.  So that will be added fuel for the next resistance check 

It didn't quite have the steam to break out...this time.

News today:
MIV Therapeutics Wins 2005 Frost & Sullivan Award for Technology Innovation in the Field of Advanced Medical Coatings

http://biz.yahoo.com/prnews/051019/daw045.html?.v=26

PALO ALTO, Calif., Oct. 19 /PRNewswire/ -- Frost & Sullivan's recent analysis, Advanced Coatings for Medical Devices and Drug Delivery, selected MIV Therapeutics Inc. (OTC Bulletin Board: MIVT - News) as the recipient of the 2005 Technology Innovation Award for developing and commercializing the next generation of biocompatible coatings for stents and other medical devices.

Each year Frost & Sullivan presents this award to a company (or individual) that has carried out new research; which has resulted in innovation(s) that have or are expected to bring significant contributions to the industry in terms of adoption, change, and competitive posture. The award recognizes the quality and depth of a company's research and development program, as well as the vision and risk-taking that enabled it to undertake such an endeavor.

"MIVT's biocompatible coating technologies are making stents safer as they are non-toxic and do not induce thrombogenicity, allergic, or inflammatory reactions," says Frost & Sullivan Industry Analyst Anil Naidu. "The company's pioneering Hydroxyapatite (HAp) coatings enable the surface of metallic stents to virtually mimic the natural state of structurally-sound 100 percent biocompatible and bio-active tissue."

A majority of currently available drug eluting stents utilize anti-proliferative and anti-inflammatory drugs embedded in a polymer matrix to prevent the problem of restenosis, which is a common complication seen with bare metal stents. Studies on bare metal stents made up of stainless steel have confirmed that the release of metal ions, such as nickel and chromium, may initiate allergic reactions or inflammatory response. This in turn may lead to restenosis (re-blocking of the arteries following angioplasty) or thrombosis (blood clotting).

To address such problems, researchers are developing coatings with improved biocompatibility that do not leach metal ions into neighboring tissues. MIVT has adopted two distinctive routes for fabricating 'nature made' coatings for stents. The first approach is a 100 percent synthetic HAp in the form of ultra-thin (sub-micron) coating and the second approach is a HAp combined with bio-polymer, for increased toughness and desired, long term/small dose drug delivery characteristics offered by the thicker coatings.

HAp resembles the human bone and is utilized on cardiovascular stents to prevent blockage of arteries due to coronary artery disease (CAD). Research has indicated that MIVT's coatings do not trigger a variety of the adverse and inflammatory reactions that are associated with products available currently, and potentially help reduce restenosis and, in particular, reduce the risk of thrombogenic events attributable in some instances to polymer-coated stents.

For coating its drug-eluting HAp-based stents, MIVT employs electrostatic-assisted deposition techniques of ceramic and the polymer through either co-deposition or post impregnation. These techniques help in the uniform deposition of composite HAp films on even complex shaped stents and assure uniform and homogenous inter-penetration of the ceramic and the bio-polymer phases. Moreover, the composite character of MIVT's HAp coating allows for the inclusion of pre-determined amounts of drug in the micropores of the coating while maintaining its mechanical robustness.

"MIVT's proprietary, patented coating not only has superior biocompatibility, but may also prove to have drug-eluting characteristics that will be more advantageous than those of polymer coatings currently available in the market," notes Naidu. "HAp is expected to stay on the stent surface for prolonged periods of time more than one year or, alternatively, can dissolve gradually within 3-12 months."

MIVT's HAp coatings are entirely biocompatible and promote tissue healing while demonstrating the optimal growth of endothelium. The company's development of such a breakthrough in advanced biocompatible medical coatings for stents and other medical devices has been recognized with Frost & Sullivan's prestigious Award for Technology Innovation.

[setravis]

I believe you'll find another test of your drawn support line. I got a great price today and I'm sure many others did, too. So that will be added fuel for the next resistance check

It didn't quite have the steam to break out...this time.

I see we had a dip potato chip!
Yes it does look like we will test the support line.
Good luck with your trade....Make some $$$$

[setravis]

When it dips, continues to bounce well off it's 50-day EMA.
On a long-term technical basis, the stock is trading above its 200-day EMA which implies it is in a positive trend.

Support @ $1.46...1.37...1.30...1.24...1.09
Resistance @ $1.55...1.82
MACD is Bearish
Stochastic is bullish

Technicals
Last Price Quote is:
1.63%above 13-day EMA
15.70%above 50-day EMA

[422fwhp]

Well, today's candle wasn't quite the "third soldier" I was hoping for...more like "two soldiers and a pet dog.  A dog named Doji.   

When does MACD turn bullish...crossover?  It looks as if it's starting to turn but you never know.

Great news for MIVT today...I made some highlights.

MIV Therapeutics' Proprietary Stent Coating Studies Presented at Major TCT Conference by Independent Researchers

VANCOUVER, British Columbia--(BUSINESS WIRE)--Oct. 25, 2005--MIV Therapeutics, Inc. (OTCBB:MIVT - News; FWB:MIV), a developer of next-generation biocompatible stent coatings and drug delivery technologies for the treatment of cardiovascular disease, announced that an independent research organization has presented interim results of a long-term animal study of its novel, biocompatible stent coating technology at the world's largest scientific convention on interventional cardiovascular therapies, the 17th annual Transcatheter Cardiovascular Therapeutics (TCT) 2005 conference, which ended Friday in Washington, D.C.
The independent researchers conducting the study concluded from interim results that the the new Hydroxyapatite (HAp) stent coatings that MIVT has developed show promise of excellent long-term biocompatibility, making the coatings a strong candidate to be a next-generation stent coating. Release of six-month follow-up data from an another group of animals in the study is pending.

Dr. Greg L. Kaluza, the Scientific Director at the Center for Research in Cardiovascular Interventions of The Methodist Hospital Research Institute in Houston, TX, and the lead investigator for the animal trial of the MIVT technology, presented his team's findings at the TCT conference. The TCT conference selected the Methodist study for the oral presentation in recognition of the research conducted on novel coating technologies and their potential significance to the field of vascular therapy.

Methodist's animal trial is examining MIVT's proprietary ultra-thin coatings for vascular stents. Stents are devices implanted in the arteries to prop open the blood vessels and to maintain healthy blood flow to the heart and throughout the body. MIVT has developed a next-generation line of biocompatible coatings based on a substance called Hydroxyapatite (HAp), for use as passive and drug-eluting applications on stents, and for application on other implantable medical devices.

"In the field of vascular stents and stent coatings, two pivotal, fundamental issues of concern are biocompatibility and safety," Dr. Kaluza said. "This animal trial is an important part of the MIVT's research program, and its objective was to verify the biocompatibility and safety of HAp-based ultra-thin coatings. The 3-month data allowed us to conclude that the ultra-thin hydroxyapatite coating selected for this study and intended for use together with microporous HAp coatings that carry drug eluting capability showed promise of an excellent long term biocompatibility and thus makes an attractive candidate for a next-generation stent coating. The 6-month follow-up data from another set of animals are pending."

The Methodist Hospital Research Institute's porcine study was performed in compliance with GLP (Good Laboratory Practice) guidelines, CE-Mark and FDA requirements.

"The study provided interim critical data that reinforced findings of our preliminary research that has indicated exceptional safety and biocompatibility of our proprietary coating technologies," said Arc W. Rajtar, Chief Technology Officer at MIVT Therapeutics. "This uncompromised biocompatibility stands behind the potential of MIVT's HAp coating technologies and their forecasted therapeutic advantages over the existing coatings and stent technologies currently available to the biomedical industry."

"The presentation by Dr. Kaluza was well-received and generated a great deal of interest within the medical device industry and between medical practitioners," said Mr. Rajtar. "Performance of our proprietary coatings in the animal model reinforced our long-standing confidence about the potential of our technologies to have a major impact in improving the efficacy and success of vascular stents and the quality of life for countless patients implanted with vascular stents and the variety of other medical devices."

Dr. Kaluza's presentation was entitled, "Biocompatibility of a Novel Ultra-Thin Hydroxyapatite Stent Coating in Normal Porcine Coronary Arteries." The presentation included scientific data gathered 3 months after implanting of stainless stents coated with highly-crystallinic calcium phosphate ceramic implanted in the coronary arteries of Yucatan minipigs.

The annual TCT conference is the preeminent scientific forum for the field of interventional vascular therapy and related fields, and is attended by more than 10,000 physicians, health care providers and professionals.

MIV Therapeutics is developing a diverse suite of HAp coating formulas to enable the surface of stents and other implanted devices to virtually mimic the natural state of structurally-sound 100% biocompatible and bio-active tissue. Hydroxyapatite, unlike polymer coatings, is naturally derived and found in such hard tissues and bioceramic materials as human bone and teeth. Research has indicated that MIVT's HAp coatings do not trigger the various adverse and inflammatory reactions that are often associated with implantation of polymer-coated stents and other foreign substances. HAp coatings are also expected to reduce the risk of thrombogenic (blood clotting) events attributable in some instances to polymer-coated stents.  Some of the most recent information presented at the TCT 2005 conference estimated that thrombogenicity was identified in 20,000 cases of implanted drug-eluting stents to date, resulting in approximately 8,000 premature deaths.

[setravis]

Holding up.
Support @ $1.46...1.36...1.30...1.09
Resistance @ $ 1.55...1.68...1.81
MACD is Bullish
Stochastic is Bullish
Recent CandleStick Analysis
Very Bullish
Oct-25-2005 DOJI 

Technicals
Last Price Quote is:
2.07%above 13-day EMA
15.76%above 50-day EMA

[422fwhp]

Still looks to be following your last drawn line (good job, btw, applaud).

This gem is still being discovered in the field and is looking great, imo.

MIV Therapeutics Invited to Present Latest Data on Breakthrough Biofriendly Coating at Leading Medical Device Conference

Wednesday November 2, 3:30 am ET 
Invitation Recognizes Potential of MIVT Proprietary Coating to Improve Stent and Drug-Delivery Effectiveness and Safety


VANCOUVER, British Columbia--(BUSINESS WIRE)--Nov. 2, 2005--MIV Therapeutics, Inc. (OTCBB:MIVT - News; FWB:MIV), a leading developer of new generation biocompatible coatings and advanced drug delivery systems, and its strategic research partner, the University of British Columbia, have been invited to present their latest achievements in research and development of novel coatings designed to significantly improve the therapeutic effectiveness and safety of vascular stents, drug-eluting stents and other implantable medical devices at the 2005 Materials & Processes for Medical Devices Conference on November 16, at the Park Plaza Hotel, in Boston, MA.
MIVT has developed a new line of ultra-thin and drug-eluting coatings for cardiovascular stents and other medical devices based on a material called Hydroxyapatite (HAp). Independent research studies have indicated that these HAp-based coatings provide superior biocompatibility compared to existing stent materials and coatings. The worldwide stent market currently totals approximately $6 billion, according to some estimates. Some biomedical industry analysts predict that the global market for drug-eluting stents and other drug-delivery applications will grow to $100 billion or more in coming years.

"Our presentation in Boston comes at a time when our coating technologies are maturing rapidly in preparation for introduction to the marketplace," said Alan Lindsay, Chairman and CEO of MIVT. "We have entered the final pre-commercialization phase of an intensive research and development program. The unparalleled biocompatibility of our unique coating technologies specifically addresses the weaknesses of existing products. Our solutions are designed to enable the multi-billion-dollar stent and medical device industry to create a new generation of significantly safer and more effective vascular stents and other devices."

Research directors from MIVT and the University of British Columbia (UBC) are scheduled to make the presentation entitled, "Hydroxyapatite Coatings for Coronary Stents", which will outline the progress of the research program and highlight the achievements made by the MIVT and UBC research teams. Arc Rajtar, MIVT's Chief Technology Officer, and Dr. Quanzu Yang, Ph.D., of the UBC's Department of Materials Engineering, are scheduled to deliver the presentation.

The research program to be presented focused on "wet" chemical technologies, including sol-gel, electro-chemical and electrophoretic methods of deposition, which resulted in ultra-thin (less than 1um) and micro-thin (1-10um) calcium-phosphate bio-ceramic films. The ultra-thin films are designed as a surface modification for metallic implants, and were shown to have resulted in exceptional biocompatibility for those implants. The micro-thin films were developed and evaluated also as a potential vehicle for drug delivery purposes for a variety of implantable medical devices.

"Stent coatings must withstand significant structural challenges during manufacturing and implantation, and must remain structurally sound, safe and biologically stable for years after implantation," said Mr. Rajtar. "We are pleased to report that our proprietary HAp deposition technologies successfully addressed these engineering challenges, confirmed by stringent evaluation test results, both on vitro and in-vivo, which we will also present at the Conference. These results, combined with the proven exceptional biocompatibility of our proprietary coating technologies sets a firm foundation for the development of a drug eluting platform superior to the technologies offered to the market at the present time."

The MIVT team consisted of Mr. Rajtar, Maurice Lien and Doug Smith. UBC scientists Dorna Hakimi, Muhrdad Keshmiri, Dr. Yang and Manus Tsui worked under the direction of Dr. Tom Troczynski, Ph.D., who is Vice President Coatings at MIVT as well as Professor of Ceramics, Dept. of Materials Engineering, at UBC.

The 2005 Materials & Processes for Medical Devices Conference is organized by ASM International. The focused event emphasizes science, applications and manufacturability as related to medical devices. For more information on the conference, visit http://www.asminternational.org/meddevices/.